Tibofem is a synthetic progestin used in hormone replacement therapy. It is prescribed to reduce menopausal symptoms such as hot flashes and to prevent osteoporosis. The drug works by binding to progesterone receptors in the endometrium providing progestogenic activity. It also exerts antiandrogenic effects that counteract estrogen driven proliferation. Its metabolite induces apoptosis in breast cancer cells contributing to its anticancer indication. Overall the compound modulates hormone receptors to achieve its therapeutic effects.

Tibofem is a medication classified as a selective estrogen receptor modulator used in the treatment of hormone-dependent conditions. Its pharmacological profile includes antagonism of estrogen receptors in bone tissue while acting as an agonist in the breast, leading to decreased bone resorption and preservation of bone mineral density. Clinically it is indicated for the management of osteoporosis in postmenopausal women who have not responded to other therapies. The drug works by binding to estrogen receptors and modulating their activity through conformational changes that recruit co-activator or co-repressor proteins depending on tissue type. This selective modulation reduces the risk of fractures by maintaining bone density without stimulating estrogen-dependent proliferative pathways in the breast. Pharmacokinetically the compound exhibits linear absorption after oral administration and a half-life that supports once-daily dosing. Its metabolites remain active and contribute to the overall therapeutic effect through prolonged receptor interaction. The overall mechanism ensures targeted estrogenic activity in skeletal tissue while blocking it in mammary tissue.

Tibofem may cause nausea in some patients. Headache is another frequently reported symptom. Some individuals experience mild fatigue or drowsiness. Skin reactions such as itching or rash can occur. Occasionally users notice changes in appetite or weight. Mild dizziness has been documented in clinical observations. These effects are generally temporary and vary between individuals.

Tibofem may cause mild nausea in some users. Headaches are occasionally reported during treatment. Some individuals experience temporary fatigue that usually resolves with rest. Skin irritation at the application site can occur in a small percentage of patients. Mild dizziness may be observed especially after the first few doses. Occasional breast tenderness has been documented in clinical studies. Digestive disturbances such as bloating or indigestion may appear. These effects are generally transient and do not require medical intervention unless they persist.